|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang W and Liu HT: MAPK signal pathways
in the regulation of cell proliferation in mammalian cells. Cell
Res. 12:9–18. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wada T and Penninger JM: Mitogen-activated
protein kinases in apoptosis regulation. Oncogene. 23:2838–2849.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Si L, Kong Y, Xu X, Flaherty KT, Sheng X,
Cui C, Chi Z, Li S, Mao L and Guo J: Prevalence of BRAF V600E
mutation in Chinese melanoma patients: Large scale analysis of BRAF
and NRAS mutations in a 432-case cohort. Eur J Cancer. 48:94–100.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Flaherty KT, Puzanov I, Kim KB, Ribas A,
McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K and
Chapman PB: Inhibition of mutated, activated BRAF in metastatic
melanoma. N Engl J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ascierto PA, McArthur GA, Dréno B,
Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L,
Stroyakovskiy D, Thomas L, et al: Cobimetinib combined with
vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM):
Updated efficacy results from a randomised, double-blind, phase 3
trial. Lancet Oncol. 17:1248–1260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zheng G, Tseng LH, Chen G, Haley L, Illei
P, Gocke CD, Eshleman JR and Lin MT: Clinical detection and
categorization of uncommon and concomitant mutations involving
BRAF. BMC Cancer. 15:7792015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Heidorn SJ, Milagre C, Whittaker S, Nourry
A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer
CJ, Pritchard C, et al: Kinase-dead BRAF and oncogenic RAS
cooperate to drive tumor progression through CRAF. Cell.
140:209–221. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wan PT, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ,
Barford D, et al: Mechanism of activation of the RAF-ERK signaling
pathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Larkin J, Chiarion-Sileni V, Gonzalez R,
Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M,
Rutkowski P, et al: Combined nivolumab and ipilimumab or
monotherapy in untreated melanoma. N Engl J Med. 373:23–34. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smalley KS, Xiao M, Villanueva J, Nguyen
TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y,
Nathanson KL and Herlyn M: CRAF inhibition induces apoptosis in
melanoma cells with non-V600E BRAF mutations. Oncogene. 28:85–94.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ikenoue T, Hikiba Y, Kanai F, Tanaka Y,
Imamura J, Imamura T, Ohta M, Ijichi H, Tateishi K, Kawakami T, et
al: Functional analysis of mutations within the kinase activation
segment of B-Raf in human colorectal tumors. Cancer Res.
63:8132–8137. 2003.PubMed/NCBI
|
|
20
|
Bauer J, Büttner P, Murali R, Okamoto I,
Kolaitis NA, Landi MT, Scolyer RA and Bastian BC: BRAF mutations in
cutaneous melanoma are independently associated with age, anatomic
site of the primary tumor, and the degree of solar elastosis at the
primary tumor site. Pigment Cell Melanoma Res. 24:345–351. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cremolini C, Di Bartolomeo M, Amatu A,
Antoniotti C, Moretto R, Berenato R, Perrone F, Tamborini E, Aprile
G, Lonardi S, et al: BRAF codons 594 and 596 mutations identify a
new molecular subtype of metastatic colorectal cancer at favorable
prognosis. Ann Oncol. 26:2092–2097. 2015. View Article : Google Scholar : PubMed/NCBI
|
